Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

04-06-2021 | EULAR 2021 | Conference coverage | Video

RESOLVE-1 fails to meet primary endpoint for lenabasum in patients with dcSSc

Robert Spiera discusses the phase 3 RESOLVE-1 findings for lenabasum in patients with diffuse cutaneous systemic sclerosis, highlighting the possible effects of background immunosuppressive therapy on outcome (7:11).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

14-05-2020 | Systemic sclerosis | News

Endocannabinoid system modulator shows potential for diffuse cutaneous SSc

11-11-2020 | ACR 2020 | Conference coverage | News

​​​​​​​Ziritaxestat warrants further investigation in early diffuse cutaneous systemic sclerosis

09-10-2020 | Systemic sclerosis | News

Early data show benefits of romilkimab in diffuse cutaneous SSc
Image Credits